Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Long-Term Investments (2020 - 2026)

Corvus Pharmaceuticals' Long-Term Investments history spans 7 years, with the latest figure at $10.5 million for Q1 2026.

  • Quarterly Long-Term Investments fell 12.95% to $10.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.5 million through Mar 2026, down 12.95% year-over-year, with the annual reading at $11.0 million for FY2025, 12.35% down from the prior year.
  • Long-Term Investments came in at $10.5 million for Q1 2026, down from $11.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $33.4 million in Q1 2022 to a low of $10.5 million in Q1 2026.
  • The 5-year median for Long-Term Investments is $16.1 million (2024), against an average of $17.6 million.
  • Year-over-year, Long-Term Investments decreased 10.11% in 2022 and then tumbled 40.3% in 2023.
  • Corvus Pharmaceuticals' Long-Term Investments stood at $21.9 million in 2022, then dropped by 26.3% to $16.1 million in 2023, then fell by 22.22% to $12.5 million in 2024, then decreased by 12.35% to $11.0 million in 2025, then fell by 4.5% to $10.5 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Long-Term Investments are $10.5 million (Q1 2026), $11.0 million (Q4 2025), and $11.5 million (Q3 2025).